Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
This guide highlights dividend ETFs with the lowest expense ratios and explains how expense structures influence long-term performance.
27,554 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Nike has fallen sharply from its peak, but a blue-chip brand can still offer compelling upside. This guide analyzes t...
A surge in AI inference demands is reshaping Google Cloud’s economics, forcing investors to weigh faster growth again...
A rising AI startup is inviting accredited investors to join a pre-IPO round at $0.85 per share before a March 12 dea...
Duolingo's stock sank after the company sacrificed $50 million in bookings to speed up user growth, aiming for 100 mi...
OpenAI investor Vinod Khosla signals alignment with Trump on AI policy as U.S.-China tech tensions surge. The stance ...
SDNY prosecutors seek a new trial for Tornado Cash co-founder Roman Storm in October 2026, even as U.S. agencies ackn...
Powell pledges to stay on the Federal Reserve board until the DOJ probe concludes, as Trump presses to replace him. T...
MP Materials is at the center of America’s push to secure essential minerals. This guide breaks down whether now is t...
As Warren Buffett's successor, Greg Abel has begun steering Berkshire Hathaway's portfolio with careful turns. A nota...
Tesla looks different than it did a few years ago. This article explains why here's tesla stock before 2031 might off...
Nvidia approaches Q1 FY2027 with lofty guidance and heightened scrutiny, as wall street holds breath awaiting whether...